Aptinyx logo Aptinyx Inc (NASDAQ:APTX) Director Robert J. Hombach purchased 25,000 shares of Aptinyx stock in a transaction dated Friday, January 25th. The stock was bought at an average cost of $5.53 per share, with a total value of $138,250.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website .
APTX opened at $5.44 on Tuesday. Aptinyx Inc has a 1-year low of $4.70 and a 1-year high of $32.25.
Aptinyx (NASDAQ:APTX) last issued its earnings results on Tuesday, November 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.58. The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $1.10 million. As a group, equities research analysts forecast that Aptinyx Inc will post -2.55 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new position in Aptinyx during the third quarter worth about $58,000. Strs Ohio bought a new position in shares of Aptinyx in the 3rd quarter worth $110,000. Wells Fargo & Company MN purchased a new stake in Aptinyx in the 3rd quarter valued at $185,000. American International Group Inc. purchased a new stake in Aptinyx in the 3rd quarter valued at $256,000. Finally, Rhumbline Advisers purchased a new stake in shares of Aptinyx during the 3rd quarter valued at $287,000. 64.76% of the stock is owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research note on Monday, January 21st. Cantor Fitzgerald assumed coverage on shares of Aptinyx in a research note on Wednesday, November 14th. They issued an “overweight” rating and a $40.00 price objective on the stock. Leerink Swann decreased their target price on shares of Aptinyx from $35.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday, January 17th. JPMorgan Chase & Co. downgraded shares of Aptinyx from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $30.00 to $8.00 in a report on Thursday, January 17th. Finally, BMO Capital Markets dropped their price objective on shares of Aptinyx to $18.00 and set an “outperform” rating for the company in a research note on Friday, January 18th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Aptinyx currently has a consensus rating of “Buy” and an average price target of $18.80.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Recommended Story: Trading signals using Bollinger bands Insider Buying and Selling by Quarter for Aptinyx (NASDAQ:APTX) Receive News & Ratings for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptinyx and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Aptinyx Inc (NASDAQ:APTX) Director Acquires $138,250.00 in Stock